Literature DB >> 17916373

Function analysis of sequences in human APOBEC3G involved in Vif-mediated degradation.

Li Zhang1, Jenan Saadatmand, Xiaoyu Li, Fei Guo, Meijuan Niu, Jiandong Jiang, Lawrence Kleiman, Shan Cen.   

Abstract

Human APOBEC3G (hA3G) has been identified as an anti-HIV cellular factor. As a counter measure, the HIV-1 protein Vif causes the degradation of hA3G by binding to it and directing it to the cellular proteasome. In this work, we have used hA3G deletion mutants to map the region in hA3G required for its degradation by Vif to hA3G amino acids 105-245, the linker region between the two zinc coordination motifs. A small fragment of hA3G containing only amino acids 105-245 will undergo Vif-induced degradation. However, while amino acids 105-156 of hA3G are required for Vif interaction with hA3G, they are not themselves sufficient for hA3G degradation, a process that further requires amino acids 157-245. While expression of hA3G fragments 1-156 or 157-384 (but not 246-384) can dominantly inhibit the Vif-mediated degradation of full-length hA3G, only the N-terminal fragment inhibits the Vif/hA3G interaction. Inhibition of hA3G degradation by the C-terminal hA3G fragment 157-384 appears to be related to its ability to prevent the polyubiquitination of hA3G induced by Vif, a process that is required for Vif-mediated proteosomal degradation of hA3G. Non-permissive cells stably expressing hA3G 1-156 or hA3G 157-384 are able to inhibit the replication of wild-type HIV-1, thereby verifying the inhibitory effect of these fragments upon Vif-mediated hA3G degradation and suggesting their potential in anti-HIV-1 therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17916373     DOI: 10.1016/j.virol.2007.08.027

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  28 in total

1.  HIV-1 Vif interaction with APOBEC3 deaminases and its characterization by a new sensitive assay.

Authors:  Iris Cadima-Couto; Nuno Saraiva; Ana Catarina C Santos; Joao Goncalves
Journal:  J Neuroimmune Pharmacol       Date:  2011-01-29       Impact factor: 4.147

Review 2.  Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all.

Authors:  Belete A Desimmie; Krista A Delviks-Frankenberrry; Ryan C Burdick; DongFei Qi; Taisuke Izumi; Vinay K Pathak
Journal:  J Mol Biol       Date:  2013-11-02       Impact factor: 5.469

Review 3.  The current structural and functional understanding of APOBEC deaminases.

Authors:  Ronda Bransteitter; Courtney Prochnow; Xiaojiang S Chen
Journal:  Cell Mol Life Sci       Date:  2009-06-23       Impact factor: 9.261

4.  Identification of two APOBEC3F splice variants displaying HIV-1 antiviral activity and contrasting sensitivity to Vif.

Authors:  Kara G Lassen; Silke Wissing; Michael A Lobritz; Mario Santiago; Warner C Greene
Journal:  J Biol Chem       Date:  2010-07-12       Impact factor: 5.157

5.  Small-molecule inhibition of human immunodeficiency virus type 1 replication by targeting the interaction between Vif and ElonginC.

Authors:  Tao Zuo; Donglai Liu; Wei Lv; Xiaodan Wang; Jiawen Wang; Mingyu Lv; Wenlin Huang; Jiaxin Wu; Haihong Zhang; Hongwei Jin; Liangren Zhang; Wei Kong; Xianghui Yu
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

6.  Vif of feline immunodeficiency virus from domestic cats protects against APOBEC3 restriction factors from many felids.

Authors:  Jörg Zielonka; Daniela Marino; Henning Hofmann; Naoya Yuhki; Martin Löchelt; Carsten Münk
Journal:  J Virol       Date:  2010-05-05       Impact factor: 5.103

7.  Determinants of efficient degradation of APOBEC3 restriction factors by HIV-1 Vif.

Authors:  Tayyba T Baig; Yuqing Feng; Linda Chelico
Journal:  J Virol       Date:  2014-10-01       Impact factor: 5.103

8.  From in silico hit to long-acting late-stage preclinical candidate to combat HIV-1 infection.

Authors:  Shalley N Kudalkar; Jagadish Beloor; Elias Quijano; Krasimir A Spasov; Won-Gil Lee; José A Cisneros; W Mark Saltzman; Priti Kumar; William L Jorgensen; Karen S Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  2017-12-26       Impact factor: 11.205

Review 9.  Multiple ways of targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug development.

Authors:  Jessica L Smith; Wei Bu; Ryan C Burdick; Vinay K Pathak
Journal:  Trends Pharmacol Sci       Date:  2009-12       Impact factor: 14.819

Review 10.  Human cellular restriction factors that target HIV-1 replication.

Authors:  Klaus Strebel; Jeremy Luban; Kuan-Teh Jeang
Journal:  BMC Med       Date:  2009-09-16       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.